YCM
CERO

Yakira Capital Management’s CERo Therapeutics CERO Stock Holding History

Yakira Capital Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-54
Closed -$1.2M – 318
2023
Q4 		$1.2M Hold
54
– – 0.39% 71
2023
Q3 		$1.18M Hold
54
– – 0.32% 80
2023
Q2 		$1.18M Buy
+54
New +$1.17M 0.31% 86

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
PA
Pineridge Advisors St. Charles, Missouri $350M AUM 6.38% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Yakira Capital Management's CERO Position: Q1 2024 in Review

Yakira Capital Management sold out of CERo Therapeutics (CERO) in Q1 2024, closing a stake of 54 shares — an estimated $1.2M sold.

Yakira Capital Management first reported a position in CERO in Q2 2023 and held it in 3 quarters. The position peaked at $1.2M in Q4 2023. 7 funds tracked by Wall St. Rank hold CERO as of Q1 2024.

  • Yakira Capital Management reported no remaining CERo Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Yakira Capital Management sold 54 CERo Therapeutics shares in Q1 2024, an estimated $1.2M.
  • Yakira Capital Management first reported a position in CERo Therapeutics in Q2 2023 and held it in 3 quarters.
  • Yakira Capital Management's CERo Therapeutics position peaked at $1.2M in Q4 2023.
  • 7 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2024.

Based on Yakira Capital Management's 13F filing for Q1 2024, filed 14 May 2024.